Vectorite Biomedical Inc. (TPEX:4170)
10.45
-0.60 (-5.43%)
Nov 20, 2026, 1:18 PM CST
Vectorite Biomedical Revenue
Vectorite Biomedical had revenue of 27.13M TWD in the half year ending June 30, 2026, with 14.95% growth. This brings the company's total for the last twelve months to 54.81M, down -19.28% year-over-year. In the year 2025, Vectorite Biomedical had annual revenue of 61.41M with 6.29% growth. That makes Vectorite Biomedical the 42,753rd largest company in the world by revenue and 2,135th in Taiwan.
Revenue (ttm)
54.81M
Revenue Growth
-19.28%
P/S Ratio
8.35
Revenue / Employee
n/a
Employees
n/a
Market Cap
457.41M
Revenue by Geography
- Taiwan 60.56M 98.6%
- China 848.00K 1.4%
Fiscal year ended Dec 31, 2025 See the full Vectorite Biomedical breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 61.41M | 3.64M | 6.29% |
| Dec 31, 2024 | 57.77M | 1.92M | 3.43% |
| Dec 31, 2023 | 55.85M | 12.94M | 30.15% |
| Dec 31, 2022 | 42.91M | 14.14M | 49.16% |
| Dec 31, 2021 | 28.77M | 4.23M | 17.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Meribank Biotech | 408.48M |
| Taiwan Advance Bio-Pharmaceutical | 348.54M |
| BioLASCO Taiwan | 266.56M |
| GeneReach Biotechnology | 241.13M |
| RBC Bioscience | 209.59M |
| NatureWise Biotech & Medicals | 174.62M |
| Lukas Biomedical | 170.01M |
| Neith | 32.29M |